IT1302121B1 - Use of L-carnitine derivatives as synergists in cancer treatment and for preventing metastases - Google Patents
Use of L-carnitine derivatives as synergists in cancer treatment and for preventing metastasesInfo
- Publication number
- IT1302121B1 IT1302121B1 ITRM980511A IT1302121B1 IT 1302121 B1 IT1302121 B1 IT 1302121B1 IT RM980511 A ITRM980511 A IT RM980511A IT 1302121 B1 IT1302121 B1 IT 1302121B1
- Authority
- IT
- Italy
- Prior art keywords
- carnitine
- medicament
- metastases
- preparation
- taxol
- Prior art date
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical class C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title abstract 5
- 206010027476 Metastases Diseases 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 5
- 229930012538 Paclitaxel Natural products 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 4
- 229960001592 paclitaxel Drugs 0.000 abstract 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 4
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 abstract 3
- 125000001589 carboacyl group Chemical group 0.000 abstract 3
- 108010006654 Bleomycin Proteins 0.000 abstract 2
- 229960001561 bleomycin Drugs 0.000 abstract 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010027458 Metastases to lung Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 239000003022 immunostimulating agent Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Use of an L-carnitine or its alkanoyl derivatives (I) is claimed (i) as a synergist in a medicament comprising an anticancer agent; and (ii) in the preparation of a medicament for reducing metastases. Use of an L-carnitine or its alkanoyl derivatives of formula (I) or their salts is claimed (i) as a synergist in a medicament comprising an anticancer agent; and (ii) in the preparation of a medicament for reducing metastases. [Image] R : H or 2-8C alkanoyl; X : anion. Independent claims are also included for: (1) a combination comprising: (a) taxol, acetyl L-carnitine, and propionyl L-carnitine and, optionally, L-carnitine; or (b) bleomycin, and acetyl L-carnitine and possibly L-carnitine; (2) use of (I) for the preparation of a medicament comprising taxol, carboplatin, bleomycin, or vincristine, the preparation being free of the side effects of the anticancer agent; and (3) kits comprising an anticancer agent and (I). ACTIVITY : Cytostatic; Immunostimulant; Neuroprotective; Respiratory. Balb/c mice inoculated with M109 lung cancer cells were administered taxol at 30 mg/kg i.p. on days 8, 10, 12 and 14 and acetyl L-carnitine at 100 mg/kg (os) on days 4-17. Tumor size on day 20 was 1202 mm 3>on day 20 with 5 lung metastases on day 22, compared to 1085 mm 3>and 9 metastases for taxol alone and 2305 mm 3>and 109.3 for an untreated control. MECHANISM OF ACTION : None given.
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98RM000511 IT1302121B1 (en) | 1998-07-30 | 1998-07-30 | Use of L-carnitine derivatives as synergists in cancer treatment and for preventing metastases |
| PT99936973T PT1100589E (en) | 1998-07-30 | 1999-07-27 | USE OF PROPIONYL-L-CARNITINE AND ACETYL-L-CARNITINE IN THE PREPARATION OF MEDICINES WITH ANTICANCERIGENIC ACTIVITY |
| JP2000561989A JP4703851B2 (en) | 1998-07-30 | 1999-07-27 | Use of L-carnitine and its alkanoyl derivative for the manufacture of a medicament having anticancer activity |
| EP99936973A EP1100589B1 (en) | 1998-07-30 | 1999-07-27 | Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity |
| AU51935/99A AU764807B2 (en) | 1998-07-30 | 1999-07-27 | Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| KR1020017001228A KR100645980B1 (en) | 1998-07-30 | 1999-07-27 | Use of L-carnitine and its alkanoyl derivatives in the manufacture of a medicament with anticancer activity |
| CA002338638A CA2338638C (en) | 1998-07-30 | 1999-07-27 | Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| DE69923322T DE69923322T2 (en) | 1998-07-30 | 1999-07-27 | USE OF PROPIONYL-L-CARNITINE AND ACETYL-L-CARNITINE FOR THE MANUFACTURE OF MEDICAMENTS WITH ANTIBODY EFFECT |
| HK01104774.3A HK1035677B (en) | 1998-07-30 | 1999-07-27 | Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity |
| ES99936973T ES2235499T3 (en) | 1998-07-30 | 1999-07-27 | USE OF PROPIONIL L-CARNITINE AND L-CARNITINE OIL DERIVATIVES IN THE PREPARATION OF MEDICINES WITH ANTI-BANERIGAN ACTIVITY. |
| PCT/IT1999/000242 WO2000006134A2 (en) | 1998-07-30 | 1999-07-27 | Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| AT99936973T ATE287278T1 (en) | 1998-07-30 | 1999-07-27 | USE OF PROPIONYL-L-CARNITINE AND ACETYL-L-CARNITINE FOR THE PRODUCTION OF MEDICINAL PRODUCTS WITH ANTI-CANCER EFFECT |
| US09/769,488 US6610699B2 (en) | 1998-07-30 | 2001-01-26 | Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| US10/292,823 US20030199535A1 (en) | 1998-07-30 | 2002-11-13 | Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
| US11/407,351 US20060258744A1 (en) | 1998-07-30 | 2006-04-20 | Medicament for preventing and/or treating peripheral neuropathies |
| US12/078,991 US20080194683A1 (en) | 1998-07-30 | 2008-04-09 | Medicament for preventing and/or treating peripheral neuropathies |
| US12/320,430 US20090143464A1 (en) | 1998-07-30 | 2009-01-26 | Method for preventing and/or treating peripheral Neuropathies induced by the administration of an anticancer agent |
| US12/320,422 US20090137619A1 (en) | 1998-07-30 | 2009-01-26 | Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
| JP2010181377A JP2010254717A (en) | 1998-07-30 | 2010-08-13 | Use of L-carnitine and its alkanoyl derivative for the manufacture of a medicament having anticancer activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98RM000511 IT1302121B1 (en) | 1998-07-30 | 1998-07-30 | Use of L-carnitine derivatives as synergists in cancer treatment and for preventing metastases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITRM980511A0 ITRM980511A0 (en) | 1998-07-30 |
| ITRM980511A1 ITRM980511A1 (en) | 2000-01-30 |
| IT1302121B1 true IT1302121B1 (en) | 2000-07-31 |
Family
ID=11406077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT98RM000511 IT1302121B1 (en) | 1998-07-30 | 1998-07-30 | Use of L-carnitine derivatives as synergists in cancer treatment and for preventing metastases |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT1302121B1 (en) |
-
1998
- 1998-07-30 IT IT98RM000511 patent/IT1302121B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ITRM980511A1 (en) | 2000-01-30 |
| ITRM980511A0 (en) | 1998-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vikram | Changing patterns of failure in advanced head and neck cancer | |
| Kline et al. | Chemotherapy of Leukemia L1210 in Mice with 1-β-d-Arabinofuranosylcytosine Hydrochloride: I. Influence of Treatment Schedules | |
| CA2338638A1 (en) | Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity | |
| ATE320793T1 (en) | ADMINISTRATION OF A CHEMOPROTECTIVE COMPOUND CONTAINING A THIOLE GROUP | |
| IL113581A0 (en) | Propiophenone derivatives their preparation and pharmaceutical compositions containing them and their use | |
| WO2001025397A3 (en) | Compositions and methods for tumor-targeted delivery of effector molecules | |
| YU64301A (en) | Camptothechin derivatives having antitumor activity | |
| CA2428160A1 (en) | Compositions for antitumor treatment containing ecteinascidin 743 | |
| AU728377B2 (en) | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase | |
| PL310159A1 (en) | Cylofulvenic analogues as antineoplastic agents | |
| AU2002352187A1 (en) | Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections | |
| IL137964A0 (en) | Antitumor agents | |
| PL356932A1 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
| ES2108240T3 (en) | DERIVATIVES OF THOSEMICARBAZONE OF 2-FORMILPIRIDINA, ITS PREPARATION AND ITS USE AS ANTI-TUMOR AGENTS. | |
| Lijinsky et al. | Carcinogenesis in Sprague—Dawley rats of N-nitroso-N-alkylcarbamate esters | |
| CA2116829A1 (en) | Use of a pregnane derivative | |
| IT1302121B1 (en) | Use of L-carnitine derivatives as synergists in cancer treatment and for preventing metastases | |
| IT1306124B1 (en) | Use of L-carnitine derivatives as synergists in cancer treatment and for preventing metastases | |
| MY134690A (en) | Antitumor therapy comprising distamycin derivatives. | |
| BG105216A (en) | Use of camptothecin derivatives , with reduced gastrointestinal toxicity | |
| CA2454664A1 (en) | Cancer treatment with go6976 and its related compounds | |
| AU2003221036A1 (en) | Remedies for lung cancer | |
| KR927002224A (en) | Antitumor Enhancers and Antitumor Agents | |
| AU5099696A (en) | Medicaments for the selective treatment of tumour tissues | |
| MY122570A (en) | Benzamide derivatives and drugs containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted |